[Skip to Navigation]
Sign In
Comment & Response
December 23, 2020

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab

Author Affiliations
  • 1Pharmacy Faculty, Pharmacology Department, University of Sevilla, Sevilla, Spain
  • 2Pharmacy Department, Hospital Doctor José Molina Orosa, Arrecife, Spain
JAMA Oncol. 2021;7(2):309. doi:10.1001/jamaoncol.2020.6989

To the Editor Schoenfeld et al1 presented nivolumab plus ipilimumab (N+I) combination as a feasible neoadjuvant treatment in patients with untreated oral cavity squamous cell carcinoma (OCSCC). In this trial, unvalidated efficacy end points and immature data of clinically relevant outcomes (progression-free survival and overall survival) were described. No dose-limiting toxic effects or surgical delays were observed in the N+I cohort. However, other safety data could have significant clinical implications.

Add or change institution